SecBot SecBot
PRESS-RELEASE ·Filed May 1, 2026

RYTM

Rhythm Pharmaceuticals, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · M&A
Actionable Insight ▲ Bullish

Regulatory expansion is a positive catalyst but launches are over a year away. Monitor upcoming earnings for initial European revenue forecasts and country-level pricing negotiations.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$81.81
T+0 close · May 1, 2026 · via day close
Latest settled
+32.06%
T+60 · $108.04
Vs SPY
+28.99%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 1 $81.81entry
  2. T+1 · 7mo ago +4.61%α +4.95% · $85.58
  3. T+5 · 6mo ago +15.11%α +12.76% · $94.17
  4. T+20 · 6mo ago +7.41%α +2.12% · $87.87
  5. T+60 · 4mo ago +32.06%α +28.99% · $108.04

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Rhythm Pharmaceuticals received European Commission approval for IMCIVREE (setmelanotide) to treat acquired hypothalamic obesity in adults and children aged 4+. This expands the addressable market by approximately 10,000 patients in Europe, building on the FDA approval in March 2026. Commercial launches are expected in 2027.

Key Facts

  • EC authorized IMCIVREE for acquired hypothalamic obesity in all EU member states
  • Pivotal Phase 3 TRANSCEND trial showed -19.8% placebo-adjusted BMI reduction (p<0.0001)
  • Approximately 10,000 patients in Europe with acquired HO
  • FDA approved same indication on March 19, 2026
  • Commercial launches anticipated in 2027

Financial Impact

Expands TAM by ~10,000 European patients; no revenue guidance provided

revenue

Risk Factors

  • Competition from other obesity treatments
  • Reimbursement and access challenges in Europe
  • Safety concerns including adrenal insufficiency and psychiatric events

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3285813

Track record

26 reports on RYTM

Performance horizon

8 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +31.83% at T+5 after the Nov 3, 2026 report. 10 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Bullish 5/10 Entry $107.48 Now $107.48 +0.00% settles Nov 24
  2. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
  3. Nov 4, 202612d ago Press Release Bullish 5/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
  4. Nov 3, 202613d ago 8-K Bullish 6/10 No price data
  5. Nov 3, 202613d ago Press Release Bullish 6/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
  6. Nov 2, 202613d ago Press Release Neutral 5/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
  7. Oct 13, 20264w ago Press Release Bullish 6/10 Entry $86.71 to $88.62 Now $107.48 +23.95% ▲ +2.20% +1.75% vs SPY
  8. Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $86.61 to $90.20 Now $107.48 +24.10% ▲ +4.14% +5.30% vs SPY
  9. Sep 14, 20269w ago 144 Bearish 5/10 Entry $96.77 to $99.27 Now $107.48 −11.07% ▼ −2.58% −0.47% vs SPY
  10. Aug 17, 202613w ago Insider Cluster Bearish 6/10 Entry $115.25 to $113.35 Now $107.48 +6.74% ▲ +1.65% +1.45% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens Wed (11h 35m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 1, 2026